4Bernhardt TG,Wang IN,Struck DK,et al.A protein antibiotic in the phage Qβ virion:diversity in lysis targets[J].Science,2001,292(5525):2326-2329.
5Jespers L,Sonveaux E,Festrez I,et al.Overexpression of the phage lambda lysozyme cloned in Escherichia coli:use of a degenerative mixture of synthetic ribosome binding sites and increase of the protein stability in vivo[J].Protein Eng,1991,4(4):485-492.
6Sao-José C,Parreira R,Vieira G,et al.The N-terminal region of the oenococcus oeni bacteriophage fog44 lysin behaves as a bonafide signal peptide in Escherichia coli and as a cis-inhibitory element,preventing lytic activity on oenococcal cells[J].J Bacteriol,2000,182(20):5823-5831.
7Kakikawa M,Yokoik I,Kimoto H,et al.Molecular analysis of the lysis protein Lys encoded by Lactobacillus plantrum phage phigle[J].Gene,2002,299(1-2):227-234.
8Takeda Y,Murphy JR.Bacteriophage conversion of heat-labile enterotoxin in Escherichia coli[J].J Bacteriol,1978,133(1):172-177.
9Payne RJ,Jansen VA.Understanding bacteriophage therapy as a density-dependent kinetic process[J].Theor Biol,2001,208(1):37-48.
10Merril CR,Scholl D,Adhya SL.The prospect for bacteriophage therapy in Western medicine[J].Nature,2003,2(6):489-497.
6Wright A,XZgnol M,Van deun A,et al.Epidemiology of antitubercucosis drug resistance 2007-2008:an updated analysis of the blobal project on anti-tubercucosis drug resistance surveiuance[J].Lancer,2009,373(9678):1861-1873.
7DeRiemer K,Garcia Garcia L, Bobadilla del Valle M, et al. Does DOTS work in populations with drug resistant tuberculosis[J]. Lancet, 2005,365(1) : 1239 1245.
8WHO/IUATLD. Guidelines for surveillance of drug resistance in tuberculosis[J]. Int J Tuberc Lung Dis, 1998,2(3):71-89.
9彭卫生 王英年 肖成志.新编结核病学[M].北京：中国医药科技出版社,1995.434-434.
10Fu LM, Fu Liu CS. Is Mycobacterium tuberculosis a closer relative to Gram-positive or Gram-negative bacterial pathogens?. Tuberculosis (Edinb), 2002,82 : 85-90.
